Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stenzl

Showing results (761-770 of 819) with videos related to

Pageof 82
Sort By:
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Scientific Reports|July 21, 2016
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenesStefan Winter, Pascale Fisel, Florian Büttner, et al.
European Urology|November 7, 2016
Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working GroupJustin W Collins, Abolfazl Hosseini, Christofer Adding, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
BJU International|February 9, 2012
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen studySeverine Huber, Christian Schwentner, Dirk Taeger, et al.
BJU International|March 17, 2010
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?Guillaume Ploussard, Alexander Haese, Hendrik Van Poppel, et al.
The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Pageof 82

Showing results (761-770 of 819) with videos related to

Sort By:
Pageof 82
European Urology|May 13, 2023
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHESAndrew J Armstrong, Taro Iguchi, Arun A Azad, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2025
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRaM-O Grimm, J Bedke, J Nyarangi-Dix, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2017
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerGillian Vandekerkhove, Tilman Todenhöfer, Matti Annala, et al.
JAMA Network Open|May 7, 2025
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical TrialArun A Azad, Daniel P Petrylak, Taro Iguchi, et al.
Scientific Reports|July 21, 2016
Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenesStefan Winter, Pascale Fisel, Florian Büttner, et al.
European Urology|November 7, 2016
Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working GroupJustin W Collins, Abolfazl Hosseini, Christofer Adding, et al.
European Urology|October 20, 2018
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized TrialJürgen E Gschwend, Matthias M Heck, Jan Lehmann, et al.
BJU International|February 9, 2012
Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen studySeverine Huber, Christian Schwentner, Dirk Taeger, et al.
BJU International|March 17, 2010
The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?Guillaume Ploussard, Alexander Haese, Hendrik Van Poppel, et al.
The Lancet. Oncology|October 11, 2016
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trialBrian I Rini, Arnulf Stenzl, Romauld Zdrojowy, et al.
Pageof 82